Targeting mitochondrial transfer: a new horizon in cardiovascular disease treatment
Journal of Translational Medicine · 2024-12-31 · 22 (1)
DOI: 10.1186/s12967-024-05979-x ↗At a glance
Übersichtsarbeit in Journal of Translational Medicine, published online on 2024-12-31. Written by Baile Zuo and 6 co-authors. Institution: Molecular Immunology and Immunotherapy Laboratory, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China. Major MEDLINE topics: Cardiovascular Diseases, Mitochondria. Cited 22 times so far (Crossref); 166 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Key Scientific Research Projects of Higher Education Institutions in Henan Province.
Abstract (original language)
Cardiovascular diseases (CVDs) are the leading cause of mortality among individuals with noncommunicable diseases worldwide. Obesity is associated with an increased risk of developing cardiovascular disease (CVD). Mitochondria are integral to the cardiovascular system, and it has been reported that mitochondrial transfer is associated with the pathogenesis of multiple CVDs and obesity. This review offers a comprehensive examination of the relevance of mitochondrial transfer to cardiovascular health and disease, emphasizing the critical functions of mitochondria in energy metabolism and signal transduction within the cardiovascular system. This highlights how disruptions in mitochondrial transfer contribute to various CVDs, such as myocardial infarction, cardiomyopathies, and hypertension. Additionally, we provide an overview of the molecular mechanisms governing mitochondrial transfer and its potential implications for CVD treatment. This finding underscores the therapeutic potential of mitochondrial transfer and addresses the various mechanisms and challenges in its implementation. By delving into mitochondrial transfer and its targeted modulation, this review aims to advance our understanding of cardiovascular disease treatment, presenting new insights and potential therapeutic strategies in this evolving field.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Molecular Immunology and Immunotherapy Laboratory, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, China.
- Department of Blood Transfusion, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
- Department of Clinical Laboratory, Heping Branch, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
- Department of Pathology, Shanxi Provincial People's Hospital, Taiyuan, China.
- Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China. yangyangbio@163.com.
- Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P. R. China. luan_yi@126.com.
Funding
- Key Scientific Research Projects of Higher Education Institutions in Henan Province
Cite
APA
Zuo, B., Li, X., Xu, D., Zhao, L., Yang, Y., Luan, Y., & Zhang, B. (2024). Targeting mitochondrial transfer: a new horizon in cardiovascular disease treatment. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05979-x
Vancouver
Zuo B, Li X, Xu D, Zhao L, Yang Y, Luan Y, et al. Targeting mitochondrial transfer: a new horizon in cardiovascular disease treatment. Journal of Translational Medicine. 2024;22(1). doi:10.1186/s12967-024-05979-x
BibTeX
@article{Zuo2024,
author = {Zuo, Baile and Li, Xiaoyan and Xu, Dawei and Zhao, Liping and Yang, Yang and Luan, Yi and Zhang, Bi},
title = {Targeting mitochondrial transfer: a new horizon in cardiovascular disease treatment},
journal = {Journal of Translational Medicine},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12967-024-05979-x}
}
EUVIMED